[{"data":1,"prerenderedAt":175},["ShallowReactive",2],{"drug-rimegepant":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":37,"contraindications":81,"warnings":91,"renal":92,"monitoring":93,"interactions":94,"review":95,"examples":98,"atc":104,"iran":106,"usApproval":118,"links":124,"populations":140},"rimegepant",1,{"fa":7,"en":8},"ریمژپانت","Rimegepant","nervous-system",{"fa":11,"en":12},"آنتاگونیست گیرنده CGRP","CGRP receptor antagonist",[14],{"name":15,"market":16},"Nurtec ODT","US",[18,19,20,7],"nurtec","vydura","نورتک",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":32,"refs":33},"odt-75","odt","oral","75 mg orally disintegrating tablet",{"amount":28,"unit":29,"perUnit":30,"scored":31},75,"mg","tablet",false,[16],[34],{"source":35,"section":36},"fda-nurtec","3",[38,65],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":29,"dose":49,"refs":50,"limits":53,"notes":56},"acute","migraine-acute",{"fa":42,"en":43},"حمله میگرن — ۷۵ mg در صورت نیاز (حداکثر ۷۵ mg در ۲۴ ساعت)","Acute migraine — 75 mg as needed (max 75 mg per 24 h)",{"minAge":45},{"value":46,"unit":47},18,"year","fixed",{"perDose":28,"dosesPerDay":5},[51],{"source":35,"section":52},"2.1",{"maxPerDay":28,"refs":54},[55],{"source":35,"section":52},[57],{"text":58,"refs":61},{"fa":59,"en":60},"ایمنی بیش از ۱۸ دوز در ۳۰ روز ثابت نشده. روی یا زیر زبان بدون آب.","Safety of more than 18 doses in 30 days not established. On or under the tongue, no water needed.",[62,63],{"source":35,"section":52},{"source":35,"section":64},"2.3",{"id":66,"disease":67,"label":68,"population":71,"type":73,"unit":29,"dose":74,"refs":78},"prev","migraine-prophylaxis",{"fa":69,"en":70},"پیشگیری میگرن اپیزودیک — ۷۵ mg یک روز در میان","Episodic migraine prevention — 75 mg every other day",{"minAge":72},{"value":46,"unit":47},"notCalculated",{"reason":75},{"fa":76,"en":77},"۷۵ mg یک روز در میان (نه روزانه)، با یا بدون غذا.","75 mg every OTHER day (not daily), with or without food.",[79],{"source":35,"section":80},"2.2",[82],{"id":83,"severity":84,"text":85,"refs":88},"hyper","block",{"fa":86,"en":87},"سابقه حساسیت به ریمژپانت.","History of hypersensitivity to rimegepant.",[89],{"source":35,"section":90},"4",[],[],[],[],{"status":96,"reviewer":97,"date":97},"unverified",null,[99],{"regimen":39,"formulation":23,"input":100,"expect":103},{"ageYears":101,"weightKg":102},30,60,{"perDose":28,"tabletsPerDoseRounded":5},[105],"N02CD06",{"status":107,"forms":108,"refs":113},"registered",[109],{"code":110,"en":111,"fa":112},"53652","RIMEGEPANT 75 mg OD TABLET","قرص ریمجپانت ۷۵ میلی‌گرم اد",[114],{"source":115,"section":116,"url":117},"darooyab-generic","G-5554\u002FRimegepant","https:\u002F\u002Fwww.darooyab.ir\u002FG-5554\u002FRimegepant",{"kind":119,"refs":120,"id":123},"NDA",[121],{"source":35,"section":122},"SPL approval \u002F marketing category","NDA212728",[125,128,132,135,138],{"kind":126,"url":127,"label":123},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=212728",{"kind":129,"url":130,"label":131},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d","FDA Nurtec ODT",{"kind":133,"url":134,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa620031.html",{"kind":136,"url":137,"label":105},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N02CD06",{"kind":139,"url":117,"label":8},"darooyab",{"pregnancy":141,"lactation":150,"pediatric":158,"geriatric":167},{"level":142,"text":143,"quote":146,"refs":147},"caution",{"fa":144,"en":145},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of NURTEC ODT in pregnant women.",[148],{"source":35,"section":149},"8.1",{"level":142,"text":151,"quote":154,"refs":155},{"fa":152,"en":153},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary A lactation study was conducted, and the results have established a relative infant dose of less than 1% of the maternal weight-adjusted dose and the milk-to-plasma ratio of 0.20 (see Data ) .",[156],{"source":35,"section":157},"8.2",{"level":159,"text":160,"quote":163,"refs":164},"not-established",{"fa":161,"en":162},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[165],{"source":35,"section":166},"8.4",{"level":142,"text":168,"quote":171,"refs":172},{"fa":169,"en":170},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects.",[173],{"source":35,"section":174},"8.5",1792115194686]